How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors
Alnylam Pharmaceuticals recently presented new clinical and real-world data for its cardiovascular portfolio, focusing on vutrisiran for transthyretin-mediated amyloidosis and zilebesiran for hypertension, at the American College of Cardiology’s 2026 meeting. These findings support Alnylam's RNAi platform's potential in both rare diseases and broader cardiovascular conditions. The results are seen as supportive of the company's investment narrative, although near-term focus remains on revenue guidance and dependence on the TTR franchise, with some analysts holding more bullish long-term views despite existing risks.
ALNYLAM PHARMACEUTICALS, INC. SEC Filing
This article details an SEC Form 144 filing by Alnylam Pharmaceuticals, Inc. (ALNY) on April 6, 2026, indicating a proposed sale of 2,286 shares of common stock, valued at $731,748.60, acquired through a stock award on April 1, 2026. The filing has a neutral impact and sentiment. The securities are to be sold through UBS Financial Services Inc. on NASDAQ.
Alnylam (NASDAQ: ALNY) sets 2026 virtual meeting, board elections and pay vote
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outlined details for its 2026 virtual annual meeting, scheduled for May 20, 2026. Stockholders will vote on the election of three Class I directors, an advisory "say-on-pay" vote for executive compensation, and the ratification of PricewaterhouseCoopers LLP as independent auditors. The proxy statement emphasizes Alnylam's commitment to corporate governance, including a classified board structure, robust executive compensation aligning pay with performance, and significant progress in its ESG and corporate responsibility initiatives.
Porphyria Treatment Market to Reach US$ 358.64 Million by 2032
The global Porphyria Treatment Market is projected to grow from US$235.58 million in 2025 to US$358.64 million by 2032, exhibiting a CAGR of 6.40%. This growth is driven by increased awareness of rare genetic disorders, improved diagnostic capabilities, and advancements in targeted therapies like gene therapy and RNA-based treatments. North America currently leads the market with a 41% share, while the Asia Pacific region is expected to be the fastest-growing market.
Perpetual Ltd Invests $2 Million in Alnylam Pharmaceuticals, Inc. $ALNY
Perpetual Ltd recently acquired a new stake of 5,039 shares, valued at approximately $2.00 million, in Alnylam Pharmaceuticals, Inc. Institutional investors now own 92.97% of the company, which holds a "Moderate Buy" consensus rating from analysts despite recent earnings missing estimates. Insider selling has been observed, with CEO Yvonne Greenstreet and EVP Kevin Joseph Fitzgerald selling shares totaling over $4 million in recent transactions.
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Aberdeen Group plc reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 15.6% during the fourth quarter, selling 24,550 shares but still holding 132,846 shares valued at $52.83 million. Company insiders also sold shares worth approximately $18.07 million, reducing their ownership to 1.50%. Despite the recent earnings miss and insider selling, analysts maintain a "Moderate Buy" consensus rating for Alnylam Pharmaceuticals with an average price target of $473.87.
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26
Alnylam Pharmaceuticals (ALNY) recently presented new clinical data at ACC.26 regarding its cardiovascular portfolio, highlighting the benefits of vutrisiran for patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The data showed vutrisiran improved health-related quality of life and functional outcomes across various patient demographics. Additionally, the company shared positive Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic for continuous blood pressure control.
10 Best Future Stocks to Buy for the Next 5 Years
This article identifies Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) as one of the best future stocks for the next five years, highlighting its cardiovascular portfolio and pipeline. Recent clinical data presented at ACC.26 showcased the benefits and efficacy of its RNAi therapeutic, vutrisiran, for transthyretin-mediated amyloidosis with cardiomyopathy. The company also shared positive Phase 2 safety data for zilebesiran, an investigational therapeutic for blood pressure control, which is currently in Phase 3 trials.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26
Alnylam Pharmaceuticals (ALNY) recently presented new cardiovascular data at ACC.26, drawing fresh attention to its vutrisiran in amyloidosis and zilebesiran in hypertension programs. Despite a recent 20.32% price decline, the company maintains strong long-term shareholder returns and is considered 35.2% undervalued by Simply Wall St's narrative, with a fair value of $491.92. However, a high P/E ratio of 135x, significantly above industry averages, suggests potential valuation risk if growth expectations are not met.
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price
Alnylam Pharmaceuticals has released new clinical data for its RNAi therapies, vutrisiran and zilebesiran, showcasing durable benefits for ATTR-CM patients and supporting Phase 3 trials for hypertension. The update reinforces the potential of Alnylam's RNAi franchise. Investors note the stock is currently undervalued according to analyst targets and Simply Wall St's own valuation, despite recent positive short-term momentum.
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now
Alnylam Pharmaceuticals Inc. (ALNY) is highlighted as a top high-growth healthcare stock. The company is actively working to improve the diagnosis and care coordination for patients with transthyretin-mediated amyloidosis (ATTR-CM) through initiatives with Viz.ai and the American Heart Association. Despite a recent downgrade by Jefferies due to concerns about high valuation and long-term expectations, ALNY remains an interesting biopharmaceutical company focused on RNA interference therapeutics.
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $489
Piper Sandler has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US), maintaining a target price of $489. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now
Alnylam Pharmaceuticals Inc. (ALNY) is highlighted as a high-growth healthcare stock, following its recent strategic efforts to improve care for ATTR-CM patients through collaborations with Viz.ai and the American Heart Association. Despite a recent downgrade by Jefferies to Hold with a reduced price target of $330 due to the belief that shares are "priced to perfection," the company's RNAi platform is still admired. The article also includes a promotional section for an AI stock report, suggesting AI stocks may offer greater and quicker returns than ALNY.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a "Moderate Buy" consensus rating from 26 analysts, with an average 12-month price target of $473.87. Despite missing Q results with $1.25 EPS versus $1.43 expected and $1.10 billion revenue versus $1.16 billion expected, the stock trades around $316 with a market cap of about $41.9 billion. Insider selling, including shares from CEO Yvonne Greenstreet and EVP Jeffrey Poulton, occurred last quarter, while institutional investors hold approximately 92.97% of the shares.
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation
Redburn Atlantic has initiated coverage of Alnylam Pharmaceuticals (ALNY) with a "Buy" recommendation. This new analyst coverage suggests a positive outlook for the company's stock from the firm. Further details regarding the price target or specific reasons for the buy recommendation were not provided in the snippet.
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Alnylam Pharmaceuticals announced new clinical and real-world data at ACC.26 supporting their RNAi therapeutics. Vutrisiran showed sustained improvements in quality of life and cardiovascular outcomes for ATTR-CM patients, even those with advanced disease, alongside high real-world adherence. Pooled Phase 2 safety data for zilebesiran in hypertension management also reinforced its acceptable safety profile, supporting its continued evaluation in a global Phase 3 CVOT.
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Alnylam Pharmaceuticals announced new clinical and real-world data at ACC.26, highlighting the benefits of vutrisiran for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) and zilebesiran for hypertension. Vutrisiran showed improvements in quality of life comparable to patients 11 years younger and reduced risk of advanced disease and mortality, while zilebesiran demonstrated an acceptable safety profile in Phase 2 for hypertension management. These findings reinforce the potential of RNAi therapeutics for cardiovascular diseases.
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals (ALNY) is collaborating with Viz.ai and the American Heart Association to enhance the early detection and coordinated care for ATTR-CM, a move that could broaden the patient identification for its TTR franchise. While this initiative is supportive of potential long-term revenue growth, the article emphasizes that the near-term investment narrative still heavily relies on managing pricing pressure, margin compression, and concentration risk in its drug AMVUTTRA. Despite some analysts forecasting significant revenue and earnings growth, current risks around net price erosion and high royalty burdens remain relevant.
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is collaborating with Viz.ai and the American Heart Association to implement AI-enabled care pathways for earlier diagnosis and coordinated care of ATTR-CM, a move that could strengthen its TTR franchise's revenue outlook. While these initiatives support earlier disease recognition, they don't significantly alter immediate concerns regarding pricing pressures, margin compression, and concentration risk in AMVUTTRA. The company's investment narrative projects substantial revenue and earnings growth by 2028, supported by optimistic analyst forecasts, though risks remain.
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing
This article analyzes Alnylam Pharmaceuticals Inc. (ALNY) using AI models to determine its effect on rotational strategy timing. It highlights strong near-term positive sentiment, mid-term neutrality, and long-term positive bias for ALNY. The analysis also provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging with defined entry, target, and stop-loss zones.
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Assenagon Asset Management S.A. significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 68.2% in the fourth quarter, selling over 54,000 shares. This move comes as Alnylam missed recent quarterly earnings and revenue estimates, despite holding a "Moderate Buy" consensus rating from analysts. Additionally, company insiders have recently sold over 53,000 shares worth approximately $18 million.
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8%
This article identifies three U.S. stocks—Alnylam Pharmaceuticals (ALNY), AST SpaceMobile (ASTS), and Nu Holdings (NU)—that are currently trading below their estimated intrinsic value based on cash flow analysis. Each company is highlighted for its growth prospects, market position, and specific financial details, despite some noted risks like insider selling or share dilution. The analysis suggests these stocks offer potential opportunities for investors seeking undervalued assets in a market that has seen modest growth.
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY)
Vanguard has filed an amended Schedule 13G/A for Alnylam Pharmaceuticals (ALNY), reporting zero beneficial ownership of Alnylam common stock. This filing follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately under SEC Release No. 34-39538. The amendment clarifies that the reporting entity named no longer holds reportable beneficial ownership, yet other Vanguard entities may disclose positions in separate filings.
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $425 to $527
This article provides a quick overview of current analyst ratings for Alnylam Pharmaceuticals (ALNY.US), highlighting a price target forecast ranging from $425 to $527. It includes a summary of recent analyst actions and their respective ratings and price targets.
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has outlined an ambitious growth strategy, targeting a 25% Compound Annual Growth Rate (CAGR) through 2030 and aiming for $4.4 billion to $4.7 billion in revenue by 2026. The company plans to achieve 30% operating margins, potentially rising to mid-40% levels, and will reinvest 30% of sales into R&D to advance its RNAi therapy pipeline. Key growth drivers include AMVUTTRA and expansions into new tissues, reinforcing its leadership in rare genetic disease treatments despite emerging competition.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights significant options trading activity, often referred to as "whale alerts," in ten healthcare stocks. These alerts indicate large transactions by institutional investors that could signal future price movements. The report details specific put and call options, their strike prices, expiration dates, and sentiment (bullish/bearish) for each of the ten companies mentioned.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright
HC Wainwright reissued a "Buy" rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $510 price target, indicating a 56.8% upside despite the company missing quarterly EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus, driven by strong commercial momentum for Amvuttra and strategic expansions utilizing AI partnerships to enhance ATTR-CM diagnosis and uptake. Insider transactions show EVPs selling shares, while institutional investors have adjusted their stakes.
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Alnylam Pharmaceuticals is collaborating with Viz.ai and the American Heart Association to improve the detection and care of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The initiatives aim to facilitate earlier diagnosis through AI-powered tools and strengthen coordinated care by sharing best practices among health systems. These efforts reflect Alnylam's commitment to transforming ATTR-CM management by addressing underdiagnosis and fragmented care.
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness
Alnylam Pharmaceuticals (ALNY) has experienced recent share price weakness, with a 23.0% year-to-date decline, despite strong longer-term returns. Simply Wall St's analysis suggests ALNY is undervalued, with a fair value of $491.92 compared to its last close of $308.05, driven by the strong uptake of AMVUTTRA and projected double-digit revenue growth. However, this valuation relies on ambitious growth assumptions and could be affected by pricing pressures or over-reliance on the TTR franchise.
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care
Alnylam Pharmaceuticals has partnered with Viz.ai and the American Heart Association to enhance the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM). This collaboration will leverage Viz.ai's artificial intelligence platform to identify potential ATTR-CM patients through cardiac imaging, aiming to improve early detection and patient care pathways for this often-underdiagnosed condition. The initiative seeks to expand educational resources and support for both healthcare professionals and patients.
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care
Alnylam Pharmaceuticals has partnered with Viz.ai and the American Heart Association to improve the identification and diagnosis of ATTR-CM, a rare and often underdiagnosed heart condition. The collaboration aims to leverage artificial intelligence and educational initiatives to reduce diagnostic delays and improve patient outcomes. This initiative seeks to increase awareness and streamline the diagnostic pathway for this critical disease.
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM
Alnylam Pharmaceuticals (ALNY) continues to see strong growth primarily due to high demand for its drug Amvuttra in treating ATTR-CM. The company, a pioneer in RNA interference therapeutics, designs small interfering RNA (siRNA) to silence disease-causing genes. This innovative approach positions Alnylam as a key player in treating difficult genetic diseases.
Immutrin raises $87M to advance drug for progressive heart disease
U.K.-based biotechnology company Immutrin has successfully raised $87 million in a Series A funding round to further develop its primary drug candidate for transthyretin amyloid cardiomyopathy (ATTR-CM), a genetic and progressive heart disease. The funds will support an early-stage clinical trial for their antibody drug, which aims to leverage the immune system to clear accumulated transthyretin deposits, a mechanism distinct from current treatments offered by companies like Pfizer, BridgeBio, and Alnylam. The company believes its approach could also address other forms of amyloidosis.
Alnylam stock price target maintained at $460 by BofA Securities
BofA Securities has reiterated a Buy rating and a $460 price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) shares, despite the stock declining 23% year-to-date. The company has identified a larger-than-expected market for ATTR-CM, now estimating over 500,000 patients globally, leading to projected earnings per share of $9.69 in fiscal 2026. Alnylam is actively pursuing initiatives to improve patient awareness and earlier diagnosis, including a collaboration with Viz.ai for AI-enabled diagnostic tools.
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
Viz.ai has partnered with Alnylam Pharmaceuticals to develop an AI Care Pathway aimed at the earlier identification and standardized diagnostic evaluation of patients with cardiac amyloidosis. This collaboration will leverage AI echocardiography analysis and generative AI to surface patients, guide clinicians through guideline-based next steps, and coordinate care across cardiology and heart failure teams. The goal is to reduce diagnosis delays and improve patient outcomes for this serious and underdiagnosed cause of heart failure.
Alnylam backs AI screening and a 10-site effort for missed heart disease
Alnylam Pharmaceuticals announced a strategic collaboration with Viz.ai to develop an AI-powered care pathway for earlier detection and improved coordination of care for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Complementing this, Alnylam is also supporting a national initiative led by the American Heart Association, bringing together 10 multidisciplinary health systems to identify care gaps and scale effective models for ATTR-CM diagnosis and management. These efforts aim to address the significant underdiagnosis and fragmented care of this progressive heart failure condition, ultimately leading to earlier intervention and improved patient outcomes.
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY
Congress Asset Management Co. significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 126.6% in Q4, acquiring 269,239 shares valued at $107.1 million. This increase occurred despite Alnylam missing Q4 earnings and revenue estimates. Analysts maintain a "Moderate Buy" consensus for ALNY with a target price of $468.84.
Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge
Alnylam Pharmaceuticals (ALNY) has reported achieving $3 billion in revenue for 2025 by leveraging the strong growth in its TTR franchise, which saw a 151% increase. This significant revenue milestone highlights the success of Alnylam's strategic focus and the market's reception of its RNAi therapeutics. The company's performance underscores its strong position in the biotechnology sector.
Polar Asset Management Partners Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Polar Asset Management Partners Inc. significantly cut its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 57.3% in the third quarter, selling 5,496 shares and retaining 4,104 shares valued at $1.87 million. This move comes as company insiders have also been net sellers, with EVPs Pushkal Garg and Kevin Fitzgerald selling a combined 4,532 shares recently. Alnylam's latest quarterly earnings and revenue missed analyst estimates, though revenue still showed substantial year-over-year growth.
Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY
Alnylam Pharmaceuticals has initiated a research collaboration with Tenaya Therapeutics, focusing on validating gene targets for cardiovascular disease. This partnership, which includes an upfront payment and significant milestone eligibility for Tenaya, aims to expand Alnylam's RNAi platform into new cardiovascular indications while mitigating early scientific risk. The article discusses how this collaboration, alongside Alnylam’s existing efforts in cardiovascular outcomes with zilebesiran, could influence the company's long-term growth and address potential future pressures on its existing TTR franchise.
Can Alnylam's Pipeline Medications Drive Sustainable Growth in the Future?
Alnylam Pharmaceuticals (ALNY) saw substantial revenue growth in 2025, driven by its four FDA-approved medications and strategic partnerships. The company is investing heavily in a robust pipeline of drug candidates including cemdisiran, zilebesiran, and mivelsiran, with some already showing promising clinical trial results. Despite strong product performance, Alnylam's stock has underperformed, and its valuation is high compared to the industry average, with analyst estimates for future earnings recently trimmed.
Groupama Asset Managment Purchases 2,483,697 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Groupama Asset Management significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 160.4% in the third quarter, acquiring an additional 2,483,697 shares. Despite this strong institutional buying, insider selling has also been reported, with CEO Yvonne Greenstreet and EVP Kevin Fitzgerald selling shares worth a combined total of over $4.3 million. Alnylam recently missed its quarterly earnings estimates, though revenue saw an 84.9% year-over-year increase, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $468.84.
Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY
Alnylam Pharmaceuticals has entered a research collaboration with Tenaya Therapeutics to explore up to 15 cardiovascular disease targets using its RNAi platform, with an upfront payment and substantial milestone eligibility. This move signifies Alnylam's strategy to expand beyond rare diseases into broader cardiometabolic indications, thereby diversifying its long-term pipeline and potentially mitigating risks associated with its existing TTR franchise. Investors should consider how this collaboration, alongside other cardiovascular initiatives, could influence Alnylam's growth trajectory and address concerns about revenue concentration and pricing pressures.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Tenaya Cardiovascular Partnership
Alnylam Pharmaceuticals (ALNY) has formed a new partnership with Tenaya Therapeutics to access up to 15 cardiovascular gene targets, with potential milestones up to US$1.13 billion. Despite a recent share price decline, the article suggests Alnylam is 35.2% undervalued with a fair value of $491.92, driven by projected aggressive growth and profitability for its RNAi therapies. However, its high P/E ratio of 134.8x, significantly above peers, indicates potential valuation risk if growth expectations aren't met.
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Alnylam Pharmaceuticals (NASDAQ: ALNY) has significantly outperformed the market over the last 20 years, achieving an average annual return of 15.87%. An initial investment of $100 in ALNY stock two decades ago would now be worth $1,898.68. This demonstrates the substantial impact of compounded returns on investment growth over time.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 12.8% in February
Alnylam Pharmaceuticals (NASDAQ:ALNY) experienced a 12.8% decrease in short interest in February, with 4,572,652 shares sold short, representing about 3.5% of its shares. The company has a "Moderate Buy" consensus from analysts with an average price target of $468.84, despite missing Q4 EPS and revenue expectations and recent insider stock sales. Several brokerages adjusted price targets and ratings, and the stock currently trades around $318.91 with a market cap of $42.29 billion.
Linden Advisors LP Makes New $6.55 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY
Linden Advisors LP has made a new $6.55 million investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), acquiring 14,364 shares in the third quarter. While institutional investors own a significant portion of the company, insiders have recently been net sellers, offloading $18.07 million worth of shares. Analysts maintain a "Moderate Buy" consensus with an average price target of $468.84, despite some firms lowering their price targets.
Brevan Howard Capital Management LP Buys Shares of 6,170 Alnylam Pharmaceuticals, Inc. $ALNY
Brevan Howard Capital Management LP recently acquired 6,170 shares of Alnylam Pharmaceuticals, Inc. (ALNY) valued at approximately $2.814 million in the third quarter. This comes as company insiders sold a significant number of shares, totaling over $18 million in the last quarter, and the company missed quarterly earnings expectations. Despite some analyst downgrades, the stock currently holds a "Moderate Buy" consensus rating with an average target price of $468.84.
California Public Employees Retirement System Buys 18,060 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
The California Public Employees Retirement System increased its stake in Alnylam Pharmaceuticals, Inc. by 8.5% in the third quarter, acquiring an additional 18,060 shares to own a total of 229,641 shares valued at approximately $104.7 million. This move comes despite Alnylam missing earnings per share and revenue estimates in its latest quarterly report, though revenue did show significant year-over-year growth. Insiders have been net sellers of the stock, while analysts generally maintain a "Moderate Buy" rating with a consensus target price of $468.84.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Tenaya Cardiovascular Partnership
Alnylam Pharmaceuticals (ALNY) has partnered with Tenaya Therapeutics, gaining access to up to 15 cardiovascular gene targets and potentially earning significant milestone payments. Despite a recent stock decline, multi-year returns show strong momentum. The company is considered 35.2% undervalued by many analysts, trading at $318.91 with a fair value estimate of $491.92, largely due to the rapid uptake of its RNAi therapies.
